Prosecution Insights
Prosecution Insights
19 pending office actions • 1 client • 16 examiners • 8 art units • 0 of 19 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 17 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 17 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (26%) |
| §102 only | 3 (16%) |
| §112 only | 7 (37%) |
| No statute on record | 4 (21%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KAPUSHOC, STEPHEN THOMAS | 3 | 46.6% | +52.8% |
| VYAS, KEYUR ANILKUMAR | 2 | 51.5% | +63.5% |
| WHITEMAN, BRIAN A | 1 | 68.2% | +17.0% |
| TATGE, LEXUS MARC | 1 | — | — |
| SCHWECHTER, BRANDON ROSS | 1 | — | — |
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +48.9% |
| PAK, MICHAEL D | 1 | 58.2% | +30.6% |
| ANGELL, JON E | 1 | 70.7% | +21.1% |
| KENYON, JOHN S | 1 | 80.3% | +17.4% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.6% | +17.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17934277 | Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function Genes | KENYON, JOHN S | 49d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18157587 | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | CASH, KAILEY ELIZABETH | 32d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18051488 | Association Of T Cell Leukemia/Lymphoma Protein 1A (TCL1A) With Clonal Hematopoiesis Of Indeterminate Potential (CHIP) | KAPUSHOC, STEPHEN THOMAS | 73d overdue |
| 17934277 | Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function Genes | KENYON, JOHN S | 49d overdue |
| 18157587 | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | CASH, KAILEY ELIZABETH | 32d overdue |
| 17855053 | Methods Of Treating Decreased Bone Mineral Density With Kringle Containing Transmembrane Protein 1 (KREMEN1) Inhibitors | POLIAKOVA-GEORGAN, EKATERINA | 28d overdue |
| 17854589 | Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) Inhibitors | VYAS, KEYUR ANILKUMAR | 19d overdue |
| 17854283 | Methods Of Treating Asthma With Solute Carrier Family 27 Member 3 (SLC27A3) Inhibitors | KAPUSHOC, STEPHEN THOMAS | 12d |
| 17936715 | Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors | ANGELL, JON E | 13d |
| 17854412 | Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) Inhibitors | KAPUSHOC, STEPHEN THOMAS | 15d |
| Client (Assignee) | Pending OAs |
|---|---|
| Regeneron | 19 |
| Art Unit | Apps |
|---|---|
| 1637 | 5 |
| 1683 | 5 |
| 1636 | 2 |
| 1674 | 2 |
| 1685 | 2 |
| 1625 | 1 |
| 1687 | 1 |
| 1675 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18485592 | Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors | Regeneron Pharmaceuticals, Inc. | WHITEMAN, BRIAN A | 1636 | Other | Non-Final OA | 16d | Pending | Oct 12, 2023 |
| 18244577 | Treatment Of Endometriosis With R-Spondin 3 (RSPO3) Inhibitors | Regeneron Pharmaceuticals, Inc. | TATGE, LEXUS MARC | 1637 | §112 | Non-Final OA | 22d | Pending | Sep 11, 2023 |
| 18355108 | Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof | Regeneron Pharmaceuticals, Inc. | SCHWECHTER, BRANDON ROSS | 1674 | §102 | Non-Final OA | 34d | Pending | Jul 19, 2023 |
| 18157587 | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | Regeneron Pharmaceuticals, Inc. | CASH, KAILEY ELIZABETH | 1683 | Other | Non-Final OA | 32d overdue | Pending | Jan 20, 2023 |
| 18067085 | Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors | Regeneron Pharmaceuticals, Inc. | PAK, MICHAEL D | 1674 | Other | Non-Final OA | 21d | Pending | Dec 16, 2022 |
| 18051488 | Association Of T Cell Leukemia/Lymphoma Protein 1A (TCL1A) With Clonal Hematopoiesis Of Indeterminate Potential (CHIP) | Regeneron Pharmaceuticals, Inc. | KAPUSHOC, STEPHEN THOMAS | 1683 | §103 | Non-Final OA | 73d overdue | Pending | Oct 31, 2022 |
| 17936715 | Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors | Regeneron Pharmaceuticals, Inc. | ANGELL, JON E | 1637 | §112 | Non-Final OA | 13d | Pending | Sep 29, 2022 |
| 17934277 | Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function Genes | Regeneron Pharmaceuticals, Inc. | KENYON, JOHN S | 1625 | §102 | Non-Final OA | 49d overdue | Pending | Sep 22, 2022 |
| 17821806 | Treatment Of Inflammatory Diseases With RAS Protein Activator Like 3 (RASAL3) Inhibitors | Regeneron Pharmaceuticals, Inc. | VYAS, KEYUR ANILKUMAR | 1637 | §112 | Non-Final OA | — | Pending | Aug 24, 2022 |
| 17854283 | Methods Of Treating Asthma With Solute Carrier Family 27 Member 3 (SLC27A3) Inhibitors | Regeneron Pharmaceuticals, Inc. | KAPUSHOC, STEPHEN THOMAS | 1683 | §112 | Non-Final OA | 12d | Pending | Jun 30, 2022 |
| 17854589 | Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) Inhibitors | Regeneron Pharmaceuticals, Inc. | VYAS, KEYUR ANILKUMAR | 1637 | §112 | Non-Final OA | 19d overdue | Pending | Jun 30, 2022 |
| 17854412 | Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) Inhibitors | Regeneron Pharmaceuticals, Inc. | KAPUSHOC, STEPHEN THOMAS | 1683 | §102 | Non-Final OA | 15d | Pending | Jun 30, 2022 |
| 17855053 | Methods Of Treating Decreased Bone Mineral Density With Kringle Containing Transmembrane Protein 1 (KREMEN1) Inhibitors | Regeneron Pharmaceuticals, Inc. | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §112 | Non-Final OA | 28d overdue | Pending | Jun 30, 2022 |
| 17525336 | Synaptojanin 2 (SYNJ2) Variants And Uses Thereof | Regeneron Pharmaceuticals, Inc. | POHNERT, STEVEN C | 1683 | §103 | Non-Final OA | — | Pending | Nov 12, 2021 |
| 17443702 | Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) Inhibitors | Regeneron Pharmaceuticals, Inc. | HUDSON, AMY ROSE | 1636 | Other | Non-Final OA | 22d | Pending | Jul 27, 2021 |
| 17204636 | METHODS AND SYSTEMS FOR DETERMINING RESPONDERS TO TREATMENT | Regeneron Pharmaceuticals, Inc. | AUGER, NOAH ANDREW | 1687 | §103 | Non-Final OA | 22d | Pending | Mar 17, 2021 |
| 17194013 | Fascin-2 (FSCN2) Variants And Uses Thereof | Regeneron Pharmaceuticals, Inc. | WANG, CHANG YU | 1675 | §112 | Non-Final OA | 43d overdue | Pending | Mar 05, 2021 |
| 17095562 | METHODS AND SYSTEMS FOR IDENTIFYING, CLASSIFYING, AND/OR RANKING GENETIC SEQUENCES | Regeneron Pharmaceuticals, Inc. | HAYES, JONATHAN EDWARD | 1685 | §103 | Final Rejection | 34d | Pending | Nov 11, 2020 |
| 17091484 | Accurate And Robust Information-Deconvolution From Bulk Tissue Transcriptomes | Regeneron Pharmaceuticals, Inc. | STRIEGEL, THEODORE CHARLES | 1685 | §103 | Final Rejection | 3d overdue | Pending | Nov 06, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial